Results 221 to 230 of about 22,694 (264)
Some of the next articles are maybe not open access.
In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive
The Medical Letter on Drugs and TherapeuticsFemlyv (Millicent), an orally disintegrating tablet containing ethinyl estradiol and norethindrone acetate, has been approved by the FDA for prevention of pregnancy in females with a body mass index (BMI) ≤35 kg/m2. It is the first hormonal contraceptive to become available in an orally disintegrating tablet formulation.
openaire +2 more sources
Focus on oral hormonal contraception
Remedium. Journal about the Russian market of medicines and medical equipment, 2017Irina Shirokova, Yulia Prozherina
openaire +1 more source
Duration, recency, and type of hormonal contraceptive use and antimüllerian hormone levels
Fertility and Sterility, 2021Marissa Steinberg Weiss +2 more
exaly
Systemic hormonal contraception and risk of venous thromboembolism
Acta Obstetricia Et Gynecologica Scandinavica, 2022Oskari Heikinheimo +2 more
exaly
The Current State of Hormonal Therapy for Prostate Cancer
Ca-A Cancer Journal for Clinicians, 2002Kenneth J Pienta
exaly
ORAL CONTRACEPTIVES AND LUTEINISING HORMONE
The Lancet, 1966GriffT. Ross +2 more
openaire +1 more source
Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
Journal of Clinical Medicine, 2020Carlotta Cocchetti +2 more
exaly